Moderate

Tardive dyskinesia

Drug-induced movement disorder · Neurology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Involuntary, often orofacial, choreiform or stereotypic movements caused by chronic exposure to dopamine receptor-blocking drugs, especially antipsychotics and metoclopramide. May be irreversible, so prevention and early recognition are key, with VMAT2 inhibitors as targeted treatment.

Red flags

  • Respiratory or oesophageal dyskinesia compromising breathing/swallowing
  • Severe tardive dystonia
  • Worsening on drug withdrawal
  • Coexisting depression/suicidality with VMAT2 inhibitors (tetrabenazine)
  • Diagnostic uncertainty with progressive course

Assessment

Differential diagnosis

  • Huntington's disease and other chorea
  • Acute dystonic reaction
  • Tardive dystonia or akathisia
  • Spontaneous orofacial dyskinesia (edentulous)
  • Functional movement disorder
  • Wilson's disease

Investigations

  • Detailed drug history (antipsychotics, metoclopramide, prochlorperazine)
  • Standardised rating (AIMS - Abnormal Involuntary Movement Scale)
  • Exclude other chorea (copper studies, autoimmune screen if atypical)
  • MRI brain if focal or atypical features
  • Review indication for the causative drug

Management

  • Identify chronic dopamine-blocker exposure and characterise the movements
  • Document severity with the AIMS scale for monitoring
  • Review the ongoing need for the offending drug with the prescriber
  • Where possible, reduce or switch to a lower-risk agent (e.g. clozapine, quetiapine)
  • Avoid abruptly stopping antipsychotics which can transiently worsen movements
  • Start a VMAT2 inhibitor for troublesome persistent tardive dyskinesia
  • Avoid anticholinergics which worsen tardive dyskinesia (unlike acute dystonia)
  • Monitor response and psychiatric stability
  • Educate the patient and document informed consent for antipsychotic continuation
  • Refer refractory cases for specialist or botulinum toxin treatment

Drugs & doses

Valbenazine 40 mg PO daily, increase to 80 mg daily (VMAT2 inhibitor)
Deutetrabenazine 6 mg PO BD titrated to 24 mg BD (max 48 mg/day)
Tetrabenazine 12.5-25 mg PO TDS as alternative
Clozapine switch for antipsychotic-requiring patients
Botulinum toxin for focal tardive dystonia

Disposition

Joint neurology-psychiatry management. Specialist referral for VMAT2 inhibitor initiation and refractory cases.

Complications & pitfalls

  • Irreversible involuntary movements
  • Social stigma and functional impairment
  • Dental and oral trauma
  • Depression (tetrabenazine)
  • Respiratory/swallowing dyskinesia

Exam pearls

  • Anticholinergics help acute dystonia but worsen tardive dyskinesia
  • VMAT2 inhibitors (valbenazine, deutetrabenazine) are the evidence-based treatment
  • Prevention by using the lowest effective antipsychotic dose is paramount
  • Do not stop antipsychotics abruptly; this can unmask or worsen movements

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.